Real-world effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in chronic kidney disease.

While the Kaplan-Meier curves suggest potential benefits of SGLT2i therapy in reducing the risk of substantial eGFR decline ≥ 40% from baseline (HR: 0.87; 95% CI: 0.69–1.11; P = 0.265) and delaying the need for KRT (HR: 0.77; 95% CI: 0.53–1.11; P = 0.164), these trends did not reach statistical significance (Fig. 3 a and c).

also in 111,027 other papers